Cargando…
Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored cell surface protein overexpressed in hepatocellular carcinoma(HCC), and its overexpression is associated with poor prognosis. The diagnostic potential of GPC3 as a serum marker has been reported. In the present study, we evaluated the use...
Autores principales: | Ofuji, Kazuya, Saito, Keigo, Suzuki, Shiro, Shimomura, Manami, Shirakawa, Hirofumi, Nobuoka, Daisuke, Sawada, Yu, Yoshimura, Mayuko, Tsuchiya, Nobuhiro, Takahashi, Mari, Yoshikawa, Toshiaki, Tada, Yoshitaka, Konishi, Masaru, Takahashi, Shinichiro, Gotohda, Naoto, Nakamoto, Yasunari, Nakatsura, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514954/ https://www.ncbi.nlm.nih.gov/pubmed/28035063 http://dx.doi.org/10.18632/oncotarget.14271 |
Ejemplares similares
-
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201) -
A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014) -
A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012) -
Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013) -
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)